




Instance: composition-en-29aa13d063497263a16ff19921f8de13
InstanceOf: CompositionUvEpi
Title: "Composition for yselty Package Leaflet"
Description:  "Composition for yselty Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe6e3ada06554e7aa869b7cd7cb6684b1)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - yselty"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Yselty is and what it is used for </li>
<li>What you need to know before you take Yselty </li>
<li>How to take Yselty </li>
<li>Possible side effects </li>
<li>How to store Yselty </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What yselty is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What yselty is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Yselty contains the active substance linzagolix. It is used to treat moderate to severe symptoms of 
uterine fibroids (commonly known as myomas), which are noncancerous tumours of the uterus 
(womb). Yselty is used in adult women (over 18 years of age) of childbearing age. In some women, 
uterine fibroids may cause heavy menstrual bleeding (your  period ) and pelvic pain (pain below the 
belly button).  </p>
<p>Linzagolix blocks the action of a hormone, gonadotropin releasing hormone, that helps to regulate the 
release of female sex hormones estradiol and progesterone. These hormones trigger women s periods 
(menstruation). When blocked, the levels of the hormones estrogen and progesterone circulating in the 
body are reduced. By decreasing their levels, linzagolix stops or reduces menstrual bleeding and 
decreases pain and pelvic discomfort and other symptoms associated with uterine fibroids. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take yselty"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take yselty"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Yselty<br />
If you have any of the conditions listed below:  </p>
<ul>
<li>if you are allergic to linzagolix or any of the other ingredients of this medicine (listed in 
section 6) </li>
<li>if you are pregnant or if you think you might be pregnant or if you are breast-feeding </li>
<li>if you have osteoporosis (a condition that makes bones fragile) </li>
<li>if you have any genital bleeding of unknown origin. </li>
</ul>
<p>If you are taking Yselty together with additional hormonal therapy of estradiol and norethisterone 
acetate (also known as add-back therapy), follow the instructions in the  Do not take  section of the 
package leaflets for estradiol and norethisterone acetate. 
Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Yselty.  </p>
<p>Before you start treatment with Yselty, your doctor will discuss your medical and family history and 
relevant risk factors with you. Your doctor will also need to check your blood pressure and make sure 
you are not pregnant. You may also need a physical examination and additional checks before you 
start treatment, such as a scan to measure how strong your bones are, that will be specific to your 
medical needs and/or concerns. </p>
<p>Stop taking Yselty and get urgent medical attention if you notice: 
*  signs of liver disease:<br />
  yellowing of your skin or the whites of your eyes (jaundice). 
  nausea or vomiting, fever, severe tiredness.<br />
  dark urine, itching or upper abdominal pain. 
* if you become pregnant. </p>
<p>Talk to your doctor or pharmacist before taking Yselty if you have: 
* reduced liver or kidney function. 
Yselty is not recommended in women with severely reduced liver or moderately or severely 
reduced kidney function as the linzagolix blood level may become too high. 
* increased levels of liver enzymes in the blood. 
Temporary increased levels of liver enzymes in the blood without symptoms may occur during 
treatment with Yselty.<br />
<em> heart or blood circulation problems, a family history of changes in the electrical activity of the 
heart known as  QT prolongation  or you are taking a medicine that changes the electrical 
activity in the heart. 
* increased blood fat levels (cholesterol). These levels should be monitored during treatment as 
Yselty may lead to further increases.<br />
</em> had a fracture that was not caused by a major trauma, or other risks of bone mineral loss or 
reduced bone density. Yselty can lower bone mineral density, so your doctor may want to check 
it beforehand in this case. 
* previously suffered from depression, mood changes, thoughts about suicide or any depressive 
symptoms as these have been reported with medications that work in the same way as Yselty 
does.<br />
* if you think you might be pregnant. Yselty usually leads to a significant reduction or may even 
stop your menstrual bleeding (your  period ) during treatment and for a few weeks afterwards, 
making it difficult to recognise pregnancy. See under  Pregnancy and breast-feeding.  </p>
<p>Yselty has not been shown to provide contraception. See under  Pregnancy and breast-feeding . </p>
<p>Yselty can be used together with another tablet containing the hormones estradiol and norethisterone 
acetate (also known as hormonal add-back therapy). If prescribed to you, read the leaflet of the tablet 
containing these hormones carefully as well as this leaflet. </p>
<p>Children and adolescents 
Yselty is not recommended for children and adolescents under 18 years as it has not been studied in 
this age group. </p>
<p>Other medicines and Yselty 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines, including hormonal contraception. </p>
<p>Particularly inform your doctor or pharmacist if you are taking: 
* repaglinide (a medicine used to treat diabetes) 
* paclitaxel, sorafenib (medicines used to treat cancer) 
Yselty is not recommended if you are using one of these medicines. </p>
<p>Pregnancy and breast-feeding 
Do not use Yselty if you are pregnant or breast-feeding as it might harm your baby. If you think you 
may be pregnant or are planning to have a baby, ask your doctor for advice before taking this 
medicine. </p>
<p>If you become pregnant, stop taking Yselty and contact your doctor. Because Yselty reduces or stops 
your periods it might be difficult to recognise pregnancy. Carry out a pregnancy test if there is any 
chance you may be pregnant. </p>
<p>Women who could become pregnant should use effective non-hormonal contraception when taking 
Yselty. </p>
<p>Driving and using machines 
Yselty has no influence on the ability to drive and use machines. </p>
<p>Yselty contains lactose and sodium 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicinal product. </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take yselty"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take yselty"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Treatment with Yselty will be prescribed by a doctor who is experienced in the care of patients with 
uterine fibroids. Always take this medicine exactly as your doctor or pharmacist has told you. Check 
with your doctor or pharmacist if you are not sure. </p>
<p>Your doctor will work out the right dose of Yselty for you. The following dose options are possible:  </p>
<ul>
<li>
<p>Either 100 mg Yselty (one tablet) or 200 mg Yselty (two tablets of 100 mg), taken once daily 
together with another tablet once daily containing the hormones estradiol and norethisterone 
acetate (also known as add-back therapy). If your doctor prescribes this add-back therapy, it is 
important to always take it with your Yselty tablets as this will help to reduce side effects 
including the risk and extent of bone mineral density loss. </p>
</li>
<li>
<p>For women for whom estradiol and norethisterone acetate are not suitable, Yselty can be taken 
in a dose of one tablet of 100 mg daily alone, i.e. without estradiol and norethisterone acetate.  </p>
</li>
<li>
<p>For short-term use (up to 6 months only), Yselty 200 mg daily (two tablets of 100 mg) can be 
given without estradiol and norethisterone acetate to treat symptoms associated with large 
fibroid or uterine size. </p>
</li>
</ul>
<p>Take the recommended dose once daily. 
Start taking Yselty preferably in the first week of your menstrual cycle, which is the week you have 
bleeding. 
Swallow the tablet(s) with one glass of water, with or without food. </p>
<p>Duration of use 
Your doctor will work out how long to continue treatment, based on the risk of bone mineral density 
loss. The 200 mg dose (two tablets of 100 mg) without add-back therapy should be prescribed for no 
longer than 6 months.<br />
Your doctor will check your bone mineral density by arranging a scan after the first 12 months of 
Yselty treatment to see if treatment can continue. If you continue Yselty treatment beyond one year, 
your doctor will keep checking your bone mineral density at regular intervals. </p>
<p>If you take more Yselty than you should 
Tell your doctor if you think you have taken too much Yselty. </p>
<p>There have been no reports of serious harmful effects from taking several doses of this medicine at 
once. If Yselty is used together with the additional hormonal therapy of estradiol and norethisterone 
acetate, overdose of the hormones may cause nausea and vomiting, breast tenderness, stomach pain, 
drowsiness, fatigue and withdrawal bleeding. </p>
<p>If you forget to take Yselty 
If you miss a dose, take it as soon as you remember and then resume taking your tablet the next day as 
usual. Do not take a double dose to make up for a forgotten tablet. </p>
<p>If you stop taking Yselty 
If you would like to stop taking Yselty, talk to your doctor first. Your doctor will explain the effects of 
stopping treatment and discuss other possibilities with you. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Side effects can occur with the following frequencies: 
Very common (may affect more than 1 in 10 people) 
* hot flush </p>
<p>Common (may affect up to 1 in 10 people) 
* mood disorders, such as mood swings, affect lability (i.e. rapid changes in emotions), anxiety, 
depression, irritability, emotional disorder 
* excessive, irregular, or prolonged bleeding from the womb (uterine bleeding) 
* vaginal dryness 
* pelvic pain 
* joint pain 
* headache 
* reduction in bone mineral density or bone strength 
* increased liver enzyme blood levels 
* nausea (feeling sick), vomiting, pain in stomach region 
* constipation 
* decreased interest in sex (libido) 
* weakness 
* increased sweating 
* night sweats 
* high blood pressure </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store yselty"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store yselty"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and cardboard box after 
EXP. The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Yselty contains 
* The active substance is linzagolix. 
One tablet of Yselty 100 mg contains 100 mg linzagolix. 
* The other ingredients are: 
Tablet core: lactose monohydrate, microcrystalline cellulose, low-substituted 
hydroxypropylcellulose, hydroxypropylcellulose, croscarmellose sodium and magnesium 
stearate. See section 2  Yselty contains lactose and sodium . 
Film-coating: macrogol poly(vinyl alcohol) grafted copolymer (E1209), talc (E553b), titanium 
dioxide (E171) and iron oxide yellow (E172).  </p>
<p>What Yselty looks like and contents of the pack 
Yselty 100 mg film-coated tablets are round shaped of 10 mm diameter, pale yellow, engraved with 
 100  on one side and plain on the other side. </p>
<p>Yselty is provided in a cardboard box with 2 or 6 blisters containing 14 film-coated tablets (tablet) per 
blister. </p>
<p>Pack sizes: 28 or 84 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Theramex Ireland Limited<br />
3rd Floor, Kilmore House,<br />
Park Lane, Spencer Dock,<br />
Dublin 1<br />
D01 YEIreland </p>
<p>Manufacturer 
Patheon France 
40 boulevard de Champaret 
38300 Bourgoin Jallieu 
France </p>
<p>This leaflet was last revised in </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-29aa13d063497263a16ff19921f8de13
InstanceOf: CompositionUvEpi
Title: "Composition for yselty Package Leaflet"
Description:  "Composition for yselty Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe6e3ada06554e7aa869b7cd7cb6684b1)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - yselty"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Yselty </li>
<li>Sådan skal du tage Yselty </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What yselty is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What yselty is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Yselty indeholder det aktive stof linzagolix. Det anvendes til behandling af moderate til svære 
symptomer på godartede muskelknuder i livmoderen (som også kaldes uterusfibromer eller -myomer). 
Yselty anvendes hos voksne kvinder (over 18 år) i den fødedygtige alder. Hos nogle kvinder kan 
muskelknuder i livmoderen forårsage kraftige menstruationsblødninger og underlivssmerter. </p>
<p>Linzagolix blokerer virkningen af det gonadotropinfrigørende hormon, som medvirker til at regulere 
frigivelsen af de kvindelige kønshormoner østradiol og progesteron. Disse hormoner udløser 
menstruation. Når de blokeres, reduceres niveauet af hormonerne østrogen og progesteron, der 
cirkulerer i kroppen. Ved at sænke deres niveau standser eller reducerer linzagolix menstruationer og 
mindsker smerter, underlivsubehag og andre symptomer forbundet med muskelknuder i livmoderen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take yselty"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take yselty"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Yselty 
hvis du har nogen af nedenstående tilstande: </p>
<ul>
<li>
<p>hvis du er allergisk over for linzagolix eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i punkt 6) </p>
</li>
<li>
<p>hvis du er gravid, eller hvis du tror, du er gravid, eller hvis du ammer </p>
</li>
<li>
<p>hvis du har knogleskørhed (osteoporose) </p>
</li>
<li>
<p>hvis du har blødning fra underlivet af ukendt årsag. </p>
</li>
</ul>
<p>Hvis du tager Yselty sammen med yderligere hormonbehandling med østradiol og norethisteronacetat 
(også kendt som tillægsbehandling), skal du følge anvisningerne i afsnittet "Tag ikke…" i 
indlægssedlen for østradiol og norethisteronacetat. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Yselty. </p>
<p>Før du påbegynder behandling med Yselty, vil din læge drøfte din syge- og familiehistorie og 
relevante risikofaktorer med dig. Lægen vil desuden kontrollere dit blodtryk og sikre sig, at du ikke er 
gravid. Du kan også behøve en fysisk undersøgelse og yderligere kontroller, inden du påbegynder 
behandlingen, f.eks. en scanning til at måle, hvor stærke dine knogler er. Undersøgelsens art vil 
afhænge af dine behov for behandling og/eller dine bekymringer. </p>
<p>Stop med at tage Yselty, og søg omgående lægehjælp, hvis du bemærker: </p>
<ul>
<li>
<p>tegn på leversygdom: 
− gulfarvning af huden eller af det hvide i øjnene (gulsot). 
− kvalme eller opkastning, feber, stærk træthed. 
− mørk urin, kløe, eller smerter i den øvre del af maven. </p>
</li>
<li>
<p>hvis du bliver gravid. </p>
</li>
</ul>
<p>Kontakt lægen eller apotekspersonalet, før du tager Yselty: </p>
<ul>
<li>
<p>hvis du har nedsat lever- eller nyrefunktion. 
Yselty frarådes hos kvinder med svært nedsat leverfunktion eller moderat eller svært nedsat 
nyrefunktion, da indholdet af linzagolix i blodet ellers kan blive for højt. </p>
</li>
<li>
<p>hvis du har forhøjede niveauer af leverenzymer i blodet. 
Under behandling med Yselty kan der midlertidigt forekomme forhøjede niveauer af 
leverenzymer i blodet, uden at det giver symptomer </p>
</li>
<li>
<p>hvis du har hjerte- eller kredsløbsproblemer eller en familiehistorie med en ændring i hjertets 
elektriske aktivitet, der kaldes "QT-forlængelse", eller hvis du tager et lægemiddel, der ændrer 
hjertets elektriske aktivitet. </p>
</li>
<li>
<p>hvis du har øget indhold af fedtstof (kolesterol) i blodet. Disse niveauer bør overvåges under 
behandlingen, da Yselty kan medføre yderligere stigninger. </p>
</li>
<li>
<p>hvis du har haft et knoglebrud, der ikke skyldtes en større skade, eller andre risici for 
knoglemineraltab eller nedsat knogletæthed. Yselty kan sænke knoglemineraltætheden, så din 
læge kan overveje at tjekke det på forhånd i dette tilfælde. </p>
</li>
<li>
<p>hvis du tidligere har lidt af depression, humørsvingninger eller selvmordstanker eller har haft 
andre depressive symptomer, som er beskrevet for lægemidler, der virker på samme måde som 
Yselty. </p>
</li>
<li>
<p>hvis du tror, du måske er gravid. Yselty medfører sædvanligvis en væsentlig reduktion af din 
menstruationsblødning og kan endda standse den under behandlingen og i nogle få uger 
derefter, hvilket gør det vanskeligt at opdage graviditet. Se under "Graviditet og amning". </p>
</li>
</ul>
<p>Det er ikke påvist, at Yselty giver prævention. Se under "Graviditet og amning". </p>
<p>Yselty kan anvendes sammen med en anden tablet, der indeholder hormonerne østradiol og 
norethisteronacetat (kaldes også hormonel tillægsbehandling). Hvis du får ordineret tabletten med 
disse hormoner, skal du nøje læse den tilhørende indlægsseddel sammen med denne indlægsseddel. </p>
<p>Børn og unge 
Yselty frarådes til børn og unge under 18 år, da det ikke er undersøgt hos denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Yselty 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin, herunder hormonel prævention. </p>
<p>Kontakt især lægen eller apotekspersonalet, hvis du tager: </p>
<ul>
<li>
<p>repaglinid (et lægemiddel mod sukkersyge) </p>
</li>
<li>
<p>paclitaxel, sorafenib (lægemidler til behandling af kræft) 
Yselty frarådes, hvis du bruger et af disse lægemidler. </p>
</li>
</ul>
<p>Graviditet og amning 
Brug ikke Yselty, hvis du er gravid eller ammer, da det kan skade dit barn. Hvis du tror, du er gravid, 
eller planlægger at blive gravid, skal du spørge din læge til råds, før du tager dette lægemiddel. </p>
<p>Hvis du bliver gravid, skal du holde op med at tage Yselty og kontakte din læge. Da Yselty nedsætter 
eller standser dine menstruationer, kan det være vanskeligt at opdage graviditet. Tag en graviditetstest, 
hvis der er en mulighed for at du er gravid. </p>
<p>Kvinder, der kan blive gravide, bør anvende effektiv ikke-hormonel prævention, når de tager Yselty. </p>
<p>Trafik- og arbejdssikkerhed 
Yselty påvirker ikke evnen til at føre motorkøretøj og betjene maskiner. </p>
<p>Yselty indeholder lactose og natrium 
Hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter, skal du tale med lægen, før du tager dette 
lægemiddel. </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. tablet og er således stort set 
natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take yselty"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take yselty"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Behandling med Yselty vil blive ordineret af en læge, der har erfaring med at behandle patienter med 
muskelknuder i livmoderen. Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets 
anvisning. Er du i tvivl, så spørg lægen eller apotekspersonalet. </p>
<p>Lægen vil fastsætte den rigtige dosis Yselty til dig. Der er følgende dosismuligheder: </p>
<ul>
<li>
<p>Enten 100 mg Yselty (én tablet) eller 200 mg Yselty (to tabletter a 100 mg) én gang dagligt 
sammen med en anden tablet én gang dagligt, der indeholder hormonerne østradiol og 
norethisteronacetat (også kaldet tillægsbehandling). Hvis lægen ordinerer denne 
tillægsbehandling, er det vigtigt altid at tage den sammen med dine Yselty-tabletter, da dette 
vil være med til at reducere bivirkningerne, herunder risikoen for og graden af 
knoglemineraltab. </p>
</li>
<li>
<p>Hos kvinder, som ikke er egnet til at få østradiol og norethisteronacetat, kan Yselty tages i en 
dosis på én tablet a 100 mg dagligt alene, dvs. uden østradiol og norethisteronacetat. </p>
</li>
<li>
<p>Til kortvarig brug (kun op til 6 måneder) kan 200 mg Yselty dagligt (to tabletter a 100 mg) 
gives uden østradiol og norethisteronacetat til at behandle symptomer forbundet med store 
muskelknuder eller en stor livmoder. </p>
</li>
</ul>
<p>Tag den anbefalede dosis én gang dagligt. 
Start helst med at tage Yselty i den første uge af din menstruationscyklus, dvs. den uge, hvor du har 
blødninger. 
Synk tabletten/tabletterne med et glas vand enten med eller uden mad. </p>
<p>Anvendelsens varighed 
Din læge vil ud fra risikoen for knoglemineraltab beregne, hvor længe behandlingen skal fortsættes. 
Dosen på 200 mg (to tabletter a 100 mg) uden tillægsbehandling bør ikke ordineres længere end 
6 måneder. 
Lægen vil tjekke din knoglemineraltæthed ved at arrangere en scanning efter de første 12 måneders 
behandling med Yselty for at se, om behandlingen kan fortsætte. Hvis du fortsætter behandlingen med 
Yselty i mere end et år, vil din læge regelmæssigt kontrollere din knoglemineraltæthed. </p>
<p>Hvis du har taget for meget Yselty 
Tal med din læge, hvis du mener, at du har taget for meget Yselty. </p>
<p>Der er ikke indberettet om alvorlige skadelige virkninger ved at tage flere doser af dette lægemiddel på 
én gang. Hvis Yselty anvendes sammen med den supplerende hormonbehandling med østradiol og 
norethisteronacetat, kan for høj dosis af disse hormoner medføre kvalme og opkastning, ømme bryster, 
mavesmerter, døsighed, træthed og blødning ved ophør af behandlingen. </p>
<p>Hvis du har glemt at tage Yselty 
Hvis du glemmer en dosis, skal du tage den, så snart du kommer i tanker om det, og derefter 
genoptage behandlingen næste dag som sædvanlig. Du må ikke tage en dobbeltdosis som erstatning 
for en glemt tablet. </p>
<p>Hvis du holder op med at tage Yselty 
Hvis du gerne vil holde op med at tage Yselty, skal du først tale med din læge. Lægen vil forklare 
virkningen af at stoppe behandlingen og drøfte andre muligheder med dig. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Bivirkningerne kan optræde med følgende hyppigheder: 
Meget almindelige (kan forekomme hos mere end 1 ud af 10 personer) </p>
<ul>
<li>hedeture </li>
</ul>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>humørforstyrrelser som f.eks. humørsvingninger, hurtige ændringer i følelser (affektlabilitet), 
angst, depression, irritabilitet, følelsesmæssige forstyrrelser </p>
</li>
<li>
<p>kraftig, uregelmæssig eller langvarig blødning fra livmoderen (uterin blødning) </p>
</li>
<li>
<p>tørhed af skeden </p>
</li>
<li>
<p>underlivssmerter </p>
</li>
<li>
<p>ledsmerter </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>nedsat knoglemineraltæthed eller knoglestyrke </p>
</li>
<li>
<p>forhøjede niveauer af leverenzymer i blodet </p>
</li>
<li>
<p>kvalme, opkastning, mavesmerter </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>nedsat sexlyst (libido) </p>
</li>
<li>
<p>svaghed </p>
</li>
<li>
<p>øget svedtendens </p>
</li>
<li>
<p>nattesved </p>
</li>
<li>
<p>forhøjet blodtryk </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apoteket. Dette gælder også eventuelle 
bivirkninger, som ikke er nævnt i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store yselty"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store yselty"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisterkortet og kartonen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. Spørg på 
apoteket om, hvordan du skal bortskaffe medicinrester. Disse foranstaltninger vil medvirke til at 
beskytte miljøet. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Yselty indeholder </p>
<ul>
<li>
<p>Aktivt stof: linzagolix. 
En tablet Yselty 100 mg indeholder 100 mg linzagolix. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: 
Tabletkerne: lactosemonohydrat, mikrokrystallinsk cellulose, lavsubstitueret 
hydroxypropylcellulose, hydroxypropylcellulose, croscarmellosenatrium og magnesiumstearat. 
Se pkt. 2 "Yselty indeholder lactose og natrium". 
Filmovertræk: macrogol copolymer podet på poly(vinylalkohol) (E1209), talkum (E553b), 
titandioxid (E171) og gul jernoxid (E172). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Yselty 100 mg filmovertrukne tabletter er runde filmovertrukne gullige tabletter med en diameter på 
10 mm, med præg "100" på den ene side og glatte på den anden side. </p>
<p>Yselty leveres i en karton med 2 eller 6 blisterpakninger, der indeholder 14 filmovertrukne tabletter pr. 
blister. </p>
<p>Pakningsstørrelser: 28 eller 84 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Theramex Ireland Limited<br />
3rd Floor, Kilmore House,<br />
Park Lane, Spencer Dock,<br />
Dublin 1<br />
D01 YE64<br />
Irland </p>
<p>Fremstiller 
Patheon France 
40 boulevard de Champaret 
38300 Bourgoin Jallieu 
Frankrig </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu </p>
<p>Indlægsseddel: Information til patienten </p>
<p>Yselty 200 mg filmovertrukne tabletter 
linzagolix </p>
<p>Dette lægemiddel er underlagt supplerende overvågning. Dermed kan der hurtigt tilvejebringes nye 
oplysninger om sikkerheden. Du kan hjælpe ved at indberette alle de bivirkninger, du får. Se sidst i 
punkt 4, hvordan du indberetter bivirkninger. </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
- Gem indlægssedlen. Du kan få brug for at læse den igen. 
- Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. 
- Lægen har ordineret dette lægemiddel til dig personligt. Lad derfor være med at give lægemidlet 
til andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har. 
- Kontakt lægen eller apotekspersonalet, hvis du får bivirkninger, herunder bivirkninger, som 
ikke er nævnt i denne indlægsseddel. Se punkt 4. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-29aa13d063497263a16ff19921f8de13
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for yselty Package Leaflet for language en"
Description: "ePI document Bundle for yselty Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-29aa13d063497263a16ff19921f8de13"
* entry[0].resource = composition-en-29aa13d063497263a16ff19921f8de13

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp29aa13d063497263a16ff19921f8de13"
* entry[=].resource = mp29aa13d063497263a16ff19921f8de13
                            
                    
Instance: bundlepackageleaflet-da-29aa13d063497263a16ff19921f8de13
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for yselty Package Leaflet for language da"
Description: "ePI document Bundle for yselty Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-29aa13d063497263a16ff19921f8de13"
* entry[0].resource = composition-da-29aa13d063497263a16ff19921f8de13

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp29aa13d063497263a16ff19921f8de13"
* entry[=].resource = mp29aa13d063497263a16ff19921f8de13
                            
                    



Instance: mp29aa13d063497263a16ff19921f8de13
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product yselty"
Description: "yselty"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1606/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "yselty"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 29aa13d063497263a16ff19921f8de13ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "yselty"

* status = #current
* mode = #working

* title = "List of all ePIs associated with yselty"

* subject = Reference(mpe6e3ada06554e7aa869b7cd7cb6684b1)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#yselty "yselty"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-29aa13d063497263a16ff19921f8de13) // yselty en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-29aa13d063497263a16ff19921f8de13) // yselty da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-29aa13d063497263a16ff19921f8de13
InstanceOf: List

* insert 29aa13d063497263a16ff19921f8de13ListRuleset
    